NetworkNewsBreaks – Soleno Therapeutics, Inc. (NASDAQ: SLNO) Obtains New US Patent for DCCR to Treat PWS, SMS
Shares of Soleno Therapeutics (NASDAQ: SLNO) are up 5% following the company’s news this morning that it has received a newly-issued patent (9,757,384) from the U.S. Patent and Trademark Office protecting the use of pharmaceutical formulations of diazoxide and its salts, including the company’s diazoxide choline controlled-release tablet (DCCR), to reduce one or more aggressive behaviors in a subject with Prader-Willi syndrome (PWS) or Smith-Magenis syndrome (SMS). The patent will provide protection to the company regarding associated claims into 2035. Soleno expects to commence a phase 3 clinical trial of DCCR in PWS by year-end 2017. “This patent will further strengthen the…







